A retrospective study analyzed data from January 2008 to September 2019 regarding adult myasthenia gravis (MG) patients, using IBM MarketScan claims data. The study encompassed both commercial and Medicare patients and examined their characteristics, treatment patterns, comorbidities, and healthcare utilization. Among the 9,352 patients analyzed, common comorbidities included anxiety, depression, and diabetes, with differences in prevalence between commercial and Medicare groups. The study observed more frequent MG exacerbations in commercial patients, possibly due to gender differences, as MG may be more severe in women. Acetylcholinesterase inhibitors were the primary treatment, and healthcare costs increased significantly during exacerbations, particularly inpatient costs. The study underscored the substantial clinical and economic impact of MG exacerbations, highlighting the inadequacy of current therapies in reducing exacerbation frequency and stressing the need for new treatments and personalized management strategies.
Reference: Pisc J, Ting A, Skornicki M, et al. Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data. J Comp Eff Res. 2024 Jan;13(1):e230108. doi: 10.57264/cer-2023-0108. Epub 2023 Dec 15. PMID: 38099519.
